Drugs / GEN1044
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04424641 | Jul 2020 → Oct 2021 | cancer of unknown primary site, esophageal cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma +4 | Genmab | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN1044 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04424641 ↗ |
| Route | Intravenous | “GEN1044 will be administered intravenously” NCT04424641 ↗ |